The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan
Transplantation Proceedings · 2026-07 · 58 (6) · 1104-1113
DOI: 10.1016/j.transproceed.2026.05.014 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplantation Proceedings, 2026-07. Verfasst von Mana Kobayashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance and Quality Assurance Department, Zenyaku Kogyo Co Ltd, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Rituximab, Liver Transplantation, Graft Rejection, ABO Blood-Group System. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chugai Pharmaceutical, Nippon Zenyaku Kogyo.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacovigilance and Quality Assurance Department, Zenyaku Kogyo Co Ltd, Bunkyo-ku, Tokyo, Japan.
- Pharmacovigilance and Quality Assurance Department, Zenyaku Kogyo Co Ltd, Bunkyo-ku, Tokyo, Japan. Electronic address: takashi_ando@mail.zenyaku.co.jp.
Förderung
- Chugai Pharmaceutical
- Nippon Zenyaku Kogyo
Zitieren
APA
Kobayashi, M., Sakamoto, J., & Ando, T. (2026). The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan. Transplantation Proceedings, 58(6), 1104-1113. https://doi.org/10.1016/j.transproceed.2026.05.014
Vancouver
Kobayashi M, Sakamoto J, Ando T. The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan. Transplantation Proceedings. 2026;58(6):1104-1113. doi:10.1016/j.transproceed.2026.05.014
BibTeX
@article{Kobayashi2026,
author = {Kobayashi, Mana and Sakamoto, Junko and Ando, Takashi},
title = {The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan},
journal = {Transplantation Proceedings},
year = {2026},
volume = {58},
number = {6},
pages = {1104--1113},
doi = {10.1016/j.transproceed.2026.05.014}
}
EUVIMED